Promomed
Promomed is a Russian pharmaceutical group focused on developing, manufacturing, clinically evaluating, marketing, and distributing medicines.
Last updated August 25, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Promomed Group is a Russian pharmaceutical company whose activities span medicine development, clinical research, regulatory work, manufacturing, promotion, and distribution. Established in 2005, the group was designed from the beginning to combine clinical-trial capabilities with the promotion of medicines produced to order. Its principal manufacturing asset is the Biokhimik plant in Saransk, Mordovia, which Promomed acquired in 2015 and subsequently upgraded for the production of pharmaceutical forms including capsules and lozenges. The company also works with external manufacturing capacity for some products. The group has built a broad portfolio covering endocrinology, rheumatology, neurology, antiviral therapy, antibacterial medicines, oncology, and other therapeutic areas. Its best-known early product was Reduxin, launched in 2007 for the treatment of obesity. In 2012, Promomed collaborated with Russia's National Medical Research Center for Endocrinology and the Russian Association of Endocrinologists on a large observational study of Reduxin involving approximately 100,000 patients and 3,000 doctors across 142 Russian locations. The study helped position the company as an active participant in evidence generation and physician-oriented pharmaceutical marketing, rather than solely as a medicines manufacturer. Promomed has also emphasized domestic pharmaceutical production and full-cycle manufacturing. In 2017, its Biokhimik operation developed and commissioned production of vancomycin active pharmaceutical substance in Russia, covering the process from the relevant strain to the finished substance. The group opened a representative office in Vietnam in 2018, indicating an effort to extend its commercial presence beyond Russia. During the COVID-19 pandemic, Promomed received Russian authorization in 2020 to produce and market Areplivir, a favipiravir-based medicine. It later obtained authorization for Esperavir, based on molnupiravir, in February 2022, followed by approval for the antiviral Skyvira in April 2022. Promomed's portfolio reportedly included more than 180 medicine names in 2021 and approximately 250 by 2023. About 80 percent of the portfolio was included in Russia's list of vital and essential medicines, a designation associated with state price regulation and public-health importance. This portfolio structure reflects the group's focus on products relevant to the Russian healthcare system, including medicines used in state procurement and import-substitution programs. The group has financed expansion partly through bond placements on the Moscow Exchange. It placed bonds with an aggregate value of 1 billion Russian rubles in 2020, followed by reported placements of 5 billion rubles in 2021 and 2.5 billion rubles in 2022. These debt placements do not establish that Promomed itself is an equity-listed company. In 2023, Promomed acquired a controlling stake in pharmaceutical company Berakhim, expanding its corporate footprint. It also agreed with the Government of Moscow to establish a research center at the Pechatniki site and a biotechnology manufacturing facility at the Alabushevo site within the Technopolis Moscow special economic zone. The planned facilities were associated with advanced pharmaceuticals and domestic-production initiatives. Petr Bely is identified as the group's founder, principal shareholder, and chair of its board of directors. Promomed has also adopted an environmental, social, and governance strategy and published its first ESG report in October 2022. Overall, the company presents itself as an integrated Russian pharmaceutical platform combining branded medicines, generic and essential-drug production, clinical and regulatory capabilities, and investment in domestic manufacturing infrastructure.
History
Promomed Group was established in 2005 as a Russian pharmaceutical business intended to combine clinical research, medicine development, promotional marketing, and distribution. Its original operating model included clinical trials and the promotion of pharmaceuticals produced to order, giving the company capabilities beyond conventional wholesale distribution. The group launched Reduxin in 2007 as a medicine for obesity treatment. In 2012, it worked with the National Medical Research Center for Endocrinology and the Russian Association of Endocrinologists on a large observational study of the product. The study reportedly covered around 100,000 patients and 3,000 doctors at 142 locations across Russia, demonstrating Promomed's interest in post-market evidence and large-scale physician engagement. A major structural change came in 2015, when Promomed acquired the Biokhimik plant in Saransk. The site became the group's principal manufacturing base. An upgraded production unit began operating at the plant that year, with capabilities for pharmaceutical forms such as capsules and lozenges. The group continued to develop domestic production, and in 2017 it brought into operation what was described as Russia's first full-cycle production of vancomycin active substance, extending from a strain variant to the finished substance. Promomed expanded its international representation in 2018 by opening an office in Vietnam. Its profile rose sharply during the COVID-19 pandemic. In 2020, the company received approval to manufacture and market Areplivir, a favipiravir-based medicine for COVID-19 treatment. Promomed also began using the bond market, placing bonds on the Moscow Exchange in 2020 with a reported aggregate value of 1 billion Russian rubles. Further reported placements followed in 2021 and 2022, although these debt issues do not indicate that the company was publicly listed through equity shares. In February 2022, Russia's Ministry of Health authorized Promomed's Esperavir, based on molnupiravir. In April of the same year, the ministry approved Skyvira, another Promomed-produced COVID-19 medicine. The group also formalized an ESG program and published its first ESG report in October 2022. Promomed's portfolio grew from more than 180 medicine names in 2021 to approximately 250 by 2023. Around 80 percent was reported to be included in Russia's list of vital and essential medicines, placing the company close to regulated and publicly important segments of the domestic pharmaceutical market. Its therapeutic coverage includes endocrinology, rheumatology, neurology, antiviral and antibacterial treatment, oncology, and other areas. In 2023, Promomed acquired a controlling stake in Berakhim. It also agreed with the Government of Moscow to create a research center at Pechatniki and a biotechnology manufacturing site at Alabushevo within the Technopolis Moscow special economic zone. The planned facilities were associated with advanced medicines and import-substitution objectives. The group's main manufacturing presence remains connected with Biokhimik in Saransk, while its wider activities encompass development, clinical work, regulatory approval, manufacturing, marketing, and distribution. Petr Bely is identified as founder, principal shareholder, and chair of the board of directors.
- 2023
Expansion through Berakhim and Moscow facilities
[1]Promomed acquires control of Berakhim and agrees to develop research and biotechnology manufacturing facilities in the Technopolis Moscow special economic zone.
- 2022
Esperavir and Skyvira receive Russian approvals
[1]The Ministry of Health authorizes Esperavir in February and Skyvira in April.
- 2020
Areplivir receives approval
[1]Promomed obtains authorization to produce and market the favipiravir-based COVID-19 medicine Areplivir.
- 2018
Vietnam representative office opens
[1]Promomed establishes a representative office in Vietnam.
- 2017
Full-cycle vancomycin substance production begins
[1]The group develops and commissions a Russian full-cycle process for producing vancomycin active substance.
- 2015
Biokhimik plant is acquired
[1]Promomed acquires the Biokhimik plant in Saransk and begins upgrading its manufacturing infrastructure.
- 2012
Large Reduxin observational study begins
[1]Promomed and Russian endocrinology organizations initiate a nationwide observational study involving approximately 100,000 patients and 3,000 doctors.
- 2007
Reduxin is launched
[1]Promomed launches Reduxin as a medicine for obesity treatment.
- 2005
Promomed Group is established
[1]The pharmaceutical group is founded with a model combining clinical trials, pharmaceutical development, promotion, and distribution.
Products and positioning
A Russian integrated pharmaceutical group emphasizing domestic manufacturing, essential medicines, clinical development, and import substitution.
Obesity treatment · 2007
Reduxin
Reduxin is Promomed's early flagship medicine for obesity treatment. Launched in 2007, it became the subject of a large observational study organized with Russian endocrinology institutions in 2012. The study involved approximately 100,000 patients and 3,000 doctors across 142 locations, making Reduxin central to Promomed's clinical-evidence and physician-engagement history.
Antiviral medicine · 2020
Areplivir
Areplivir is a Promomed COVID-19 medicine developed on the basis of the favipiravir molecule. Promomed received Russian authorization to manufacture and market it in 2020 during the COVID-19 pandemic. Some production was reported to have used external manufacturing capacity in addition to the group's own facilities.
Antiviral medicine · 2022
Esperavir
Esperavir is an antiviral medicine based on molnupiravir. Russia's Ministry of Health granted Promomed marketing authorization in February 2022 for its use in the COVID-19 treatment context.
Antiviral medicine · 2022
Skyvira
Skyvira is another Promomed-produced anti-COVID medicine. It received approval from Russia's Ministry of Health in April 2022. Public reference material identifies it as part of the group's pandemic antiviral portfolio but does not provide sufficient detail here on its current commercial status.
Antibacterial active pharmaceutical ingredient · 2017
Vancomycin active pharmaceutical substance
Promomed developed and commissioned full-cycle Russian production of vancomycin active pharmaceutical substance at its Biokhimik operation. The process was described as extending from a strain variant through to the finished substance, supporting the group's domestic-manufacturing and import-substitution positioning.
Marketing campaigns
- 2012Reduxin nationwide observational study
Russia
Promomed partnered with the National Medical Research Center for Endocrinology and the Russian Association of Endocrinologists on a large observational study involving approximately 100,000 patients and 3,000 doctors at 142 Russian locations.
Outcome. The study became a major evidence-generation and professional-engagement initiative associated with Reduxin.
Brand decisions
2023
Acquire a controlling stake in BerakhimM&ABackground
Promomed continued to expand its pharmaceutical corporate platform.
Action taken
The group purchased a controlling stake in pharmaceutical company Berakhim.
Aftermath
The transaction broadened Promomed's group structure; further transaction terms are not specified in the available reference material.
2023
Establish Moscow research and biotechnology facilitiesStrategyBackground
Promomed and the Government of Moscow pursued advanced pharmaceutical production and import-substitution capacity within the Technopolis Moscow special economic zone.
Action taken
The parties agreed to create a research center at Pechatniki and a biotechnology manufacturing facility at Alabushevo.
Aftermath
The planned experimental production unit was expected to produce approximately 250,000 medicine bottles per year at its initial stage.
2017
Develop full-cycle vancomycin productionStrategyBackground
Promomed was expanding domestic production of pharmaceutical substances.
Action taken
The group developed and put into operation a Russian full-cycle process for producing vancomycin active substance.
Aftermath
The initiative strengthened the group's positioning around local pharmaceutical manufacturing and import substitution.
2015
Acquire and upgrade the Biokhimik plantM&ABackground
Promomed sought greater control over domestic pharmaceutical manufacturing capacity.
Action taken
The group acquired Biokhimik in Saransk and began upgrading production units for pharmaceutical forms including capsules and lozenges.
Aftermath
Biokhimik became the group's major production site and later supported full-cycle vancomycin substance production.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/promoned · Editorial policy · How profiles are compiled